Saturday - June 20, 2026

ANCA Vasculitis Pipeline Expands as 12+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s “ANCA Vasculitis Pipeline Insight 2026” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the ANCA Vasculitis pipeline landscape. It covers the ANCA Vasculitis Pipeline drug profiles, including clinical and nonclinical stage products. It also covers … Continue reading

Myotonic Dystrophy Market Size to Exceed USD 2.6 Billion by 2036, Driven by Emerging Disease-Modifying Therapies, Rising Diagnosed Population, and Advancements in Genetic Research | DelveInsight

The Myotonic Dystrophy Market is expected to witness substantial growth through 2036, fueled by increasing disease awareness, improved genetic testing and diagnosis, a growing patient pool, and the anticipated launch of innovative therapies targeting the underlying cause of the disease. … Continue reading

Pollen Allergy Market Size to Surpass USD 5.8 Billion by 2036, Driven by Rising Disease Burden, Immunotherapy Advancements, and Emerging Biologic Therapies | DelveInsight

The Pollen Allergy Market is projected to grow significantly through 2036, driven by the rising prevalence of seasonal allergic rhinitis, increasing allergen exposure, and greater adoption of allergen immunotherapy. Advancements in biologics, including REGN5713-5715, along with improved molecular diagnostics and … Continue reading

Fibromyalgia Market Size is Expected to Witness Significant Growth by 2036 Driven by Emerging Therapies, Expanding Treatment Landscape, and Rising Disease Burden | DelveInsight

The Fibromyalgia Market is poised for substantial growth through 2036, fueled by increasing disease prevalence, growing awareness and diagnosis rates, advances in multimodal treatment approaches, and the introduction of novel therapies. The recent approval of TONMYA and the development of … Continue reading

Spinocerebellar Ataxias Pipeline Gains Momentum with 10+ Emerging Therapies Across Clinical Development, Driven by Advances in Gene-Silencing and Regenerative Medicine

The Spinocerebellar Ataxias pipeline landscape is witnessing significant progress, fueled by increasing research into gene-targeted therapies, antisense oligonucleotides, stem cell-based approaches, and disease-modifying treatment strategies. Growing scientific understanding of the genetic mechanisms underlying Spinocerebellar Ataxias is encouraging the development of … Continue reading

HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Shows Strong Momentum as 5+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “HPV+ Recurrent/Metastatic Head and Neck Cancer Pipeline Insight 2026” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the HPV+ Recurrent/Metastatic Head and Neck Cancer pipeline landscape. It covers the HPV+ Recurrent/Metastatic Head and Neck Cancer … Continue reading

Urinary Tract Infections Pipeline Shows Strong Momentum as 38+ Pharma Companies in the Race | DelveInsight

DelveInsight’s “Urinary Tract Infections Pipeline Insight 2026” report provides comprehensive insights about 38+ companies and 38+ pipeline drugs in the Urinary Tract Infections pipeline landscape. It covers the Urinary Tract Infections Pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading

Oncolytic Virus Cancer Therapy Pipeline Shows Strong Momentum as 120+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Oncolytic Virus Cancer Therapy Pipeline Insight 2026” report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical … Continue reading